Navigation Links
CeNeRx BioPharma Announces Positive Phase I Results in First Human,Trial of Third Generation RIMA Antidepressant

- Tyrima Demonstrates Good Safety Profile and Excellent Pharmacokinetic Properties -

RESEARCH TRIANGLE PARK, N.C., March 13, 2007 /PRNewswire/ -- CeNeRx BioPharma, Inc., a clinical stage company developing and commercializing innovative treatments for diseases of the central nervous system, today announced top-line results from a Phase I clinical trial of Tyrima(TM), its lead candidate for the treatment of depression and anxiety. In this study, Tyrima was safe and well tolerated. Tyrima is a member of a novel class of drugs known as reversible inhibitors of monoamine oxidase A, or RIMAs.

The single-dose, placebo-controlled trial evaluated Tyrima in 41 subjects with doses escalating from 5 mg to 120 mg over the course of the study. Tyrima was well tolerated with no clinically significant adverse events even at the highest dose of 120 mg. Tyrima achieved high plasma concentrations that increased linearly with dose, and the favorable pharmacokinetic half-life should permit once or twice daily dosing. None of the safety and tolerability issues commonly associated with conventional monoamine oxidase A inhibitors (MAOIs) were seen in this study.

"The triple mechanism of MAOI antidepressants has the potential to provide enhanced efficacy to the 30% of patients who do not respond to current therapies, but use of these drugs has been limited by their propensity to cause serious side effects," said Dr. Atul Pande, chief medical officer of CeNeRx. "It is therefore encouraging that Tyrima, a selective and reversible MAO inhibitor specifically designed to avoid these side effects, demonstrated a promising safety profile in its first clinical trial, even at the highest dose. These results provide a strong foundation for proceeding to multiple dose safety studies."

Tyrima's unique mechanism elevates the levels of three key neurotransmitters (serotonin, norepinephrine and dopamine) that affect mood and anx
'"/>




Page: 1 2 3

Related medicine technology :

1. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
2. Array BioPharma to Present at the C.E Unterbeg, Towbin Emerging Growth Conference
3. DOR BioPharma Announces Issuance of European Patent for Its Oral Multivalent Botulinum Toxin Vaccine BT-VACC
4. DOR BioPharma Announces Publication Describing Results of Its Multivalent Botulinum Toxin Vaccine BT-VACC
5. Array BioPharma Reports New Clinical Data on Its Anti-Inflammatory Drugs
6. PDL BioPharma Announces Long-Term Nuvion Data Presented at 2007 Digestive Disease Week
7. AVI BioPharma Reports Positive Pre-Clinical Influenza Data
8. Helix BioPharma Corp. Announces Positive Phase II Clinical Results with its Topical Interferon Alpha-2b
9. Integrated BioPharmas Proprietary Vaccine Technology Achieves Strong Positive Results
10. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
11. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
Post Your Comments:
(Date:8/26/2014)... Aug. 26, 2014  Actavis plc (NYSE: ACT ... Brenton Saunders , CEO and President of Actavis, will ... the Morgan Stanley Global Healthcare Conference 2014 in ... The presentation will take place on ... the Grand Hyatt New York, 109 East 42 nd ...
(Date:8/26/2014)... , Aug. 26, 2014 Reportlinker.com ... is available in its catalogue: ... 2020 http://www.reportlinker.com/p02280977/Japan-Esophagoscopes--Gastroscopes-Market-Outlook-to-2020.html ... Outlook to 2020 Summary GlobalData,s ... Outlook to 2020", provides key market data ...
(Date:8/26/2014)... Research and Markets  has announced the ... 2014-2018" report to their offering. Intranasal ... the administration of drugs for the treatment of local ... allergic and non-allergic rhinitis and sinusitis. The nose is ... vaccination and systematic drug delivery. Continuous ...
Breaking Medicine Technology:Actavis to Present at Morgan Stanley Global Healthcare Conference 2014 2Japan Esophagoscopes & Gastroscopes Market Outlook to 2020 2Japan Esophagoscopes & Gastroscopes Market Outlook to 2020 3Japan Esophagoscopes & Gastroscopes Market Outlook to 2020 4Japan Esophagoscopes & Gastroscopes Market Outlook to 2020 5Global Intranasal Drug Delivery Market 2014-2018: Key Vendors are Becton, Dickinson and Company, GlaxoSmithKline, Johnson & Johnson and Novartis 2Global Intranasal Drug Delivery Market 2014-2018: Key Vendors are Becton, Dickinson and Company, GlaxoSmithKline, Johnson & Johnson and Novartis 3
... 2011 , The deadly E. ... thousands across Europe has been sequenced using 454,Life Sciences, ... and detailed genetic analysis to date" of this,particularly virulent ... performed by scientists at the UK,s Health,Protection Agency and ...
... 2011 Reportlinker.com announces that a ... in its catalogue: ... Number of PE/VC Investments in Small ... in the Past Four Years ...
Cached Medicine Technology:Deadly E. Coli Strain Sequenced With Roche GS Junior System by HPA Scientists - Provides Community Most Complete Assembly to Date 2Deadly E. Coli Strain Sequenced With Roche GS Junior System by HPA Scientists - Provides Community Most Complete Assembly to Date 3Reportlinker Adds PE/VC Activity in Medical Devices - Number of PE/VC Investments in Small Sized Medical Devices Companies Has Increased in the Past Four Years 2Reportlinker Adds PE/VC Activity in Medical Devices - Number of PE/VC Investments in Small Sized Medical Devices Companies Has Increased in the Past Four Years 3Reportlinker Adds PE/VC Activity in Medical Devices - Number of PE/VC Investments in Small Sized Medical Devices Companies Has Increased in the Past Four Years 4Reportlinker Adds PE/VC Activity in Medical Devices - Number of PE/VC Investments in Small Sized Medical Devices Companies Has Increased in the Past Four Years 5Reportlinker Adds PE/VC Activity in Medical Devices - Number of PE/VC Investments in Small Sized Medical Devices Companies Has Increased in the Past Four Years 6Reportlinker Adds PE/VC Activity in Medical Devices - Number of PE/VC Investments in Small Sized Medical Devices Companies Has Increased in the Past Four Years 7Reportlinker Adds PE/VC Activity in Medical Devices - Number of PE/VC Investments in Small Sized Medical Devices Companies Has Increased in the Past Four Years 8Reportlinker Adds PE/VC Activity in Medical Devices - Number of PE/VC Investments in Small Sized Medical Devices Companies Has Increased in the Past Four Years 9Reportlinker Adds PE/VC Activity in Medical Devices - Number of PE/VC Investments in Small Sized Medical Devices Companies Has Increased in the Past Four Years 10Reportlinker Adds PE/VC Activity in Medical Devices - Number of PE/VC Investments in Small Sized Medical Devices Companies Has Increased in the Past Four Years 11
(Date:8/27/2014)... 2014 Sugar Manufacturing in ... fluctuations in global supply and demand, which have contributed ... The industry derives a large share of its revenue ... market dynamics, with supply and prices being determined by ... strong Australian dollar for the majority of the past ...
(Date:8/27/2014)... 27, 2014 SCOTT Sports is ... Utah’s first indoor mountain bike and BMX park. SCOTT ... bikes in both adult and youth sizes for the park’s ... a distribution warehouse in Ogden, Utah, recently moved its U.S. ... “We are proud to be a partner with the Wasatch ...
(Date:8/27/2014)... knowledge is power, and a new UCLA study has shown ... making the best decisions about how to treat their prostate ... educated about their disease have a much more difficult time ... negatively impact the quality of their care and their long-term ... for physicians, who can use the findings to target men ...
(Date:8/27/2014)... who eat over 10 portions a week of tomatoes ... prostate cancer, new research suggests. , With 35,000 new ... deaths, prostate cancer is the second most common cancer ... countries, which some experts believe is linked to a ... dietary and lifestyle recommendations reduces risk of prostate cancer, ...
(Date:8/27/2014)... Bedros Keuilian is the founder of the fastest ... fitness boot camp marketing expert in the industry ... thing he knows very well is how to build a ... the fitness business. , In his new, hour-long webinar ... instructional guide on how fitness boot camp owners and personal ...
Breaking Medicine News(10 mins):Health News:Sugar Manufacturing in Australia Industry Market Research Report Now Updated by IBISWorld 2Health News:Sugar Manufacturing in Australia Industry Market Research Report Now Updated by IBISWorld 3Health News:Sugar Manufacturing in Australia Industry Market Research Report Now Updated by IBISWorld 4Health News:SCOTT Sports to Sponsor Wasatch Indoor Bike Park 2Health News:Men who are uneducated about their prostate cancer have difficulty making good treatment choices 2Health News:Men who are uneducated about their prostate cancer have difficulty making good treatment choices 3Health News:Fighting prostate cancer with a tomato-rich diet 2Health News:Bedros Keuilian Releases New Fitness Boot Camp Marketing Webinar on Building a Personal Brand 2Health News:Bedros Keuilian Releases New Fitness Boot Camp Marketing Webinar on Building a Personal Brand 3
... is to create therapies or simply investigate how organisms ... one of biological science's toughest assignments: keeping their tiny ... have notoriously finicky tastes, and despite a decade of ... the cells will continue dividing indefinitely in culture or ...
... to funding are needed to support the rising numbers ... experts. ,Providing quality health services that ... between Federal and State Governments, and public and private ... their editorial for the Medical Journal of Australia, Ms ...
... study shows that repeated treatments of botulinum toxin type ... in a significant decrease in spasticity, pain frequency ... according to research from a neurologist at Wake Forest ... these outcome measures indicate a better quality of life ...
... is turned on its head yet again, this time on what ... is not cotton or linen , but denim and wool, Swiss ... how people protect their skin. ,Writing in a ... the least effective option. ,The team from the ...
... primary open angle glaucoma (POAG) are not treated medically ... study. ,The study is the first investigation ... data from a nationally representative sample of Medicare patients. ... surgeries among adults aged 65 and older by analyzing ...
... the risk of developing health disorders like cardiovascular disease and ... of developing cancer, a new study says. ,Conducted ... Cancer Council of Victoria in Australia - looked into the ... waist measurement of more than 100 centimetres for men and ...
Cached Medicine News:Health News:New Technique Dissects Stem Cells' Picky Likes, Dislikes 2Health News:New Technique Dissects Stem Cells' Picky Likes, Dislikes 3Health News:Pain and Intensity Of Post-stroke Spasticity Decreased by Botox Treatment 2Health News:Denim, Not Cotton, Apt Wear for Summer 2
A system with integrated pupil camera and 7" examination monitor. An easy to use configuration....
... The Laserex Tango ophthalmic laser system ... an SLT laser and a photodisruptor for ... is a frequency-doubled Nd:YAG producing pulsed 532 ... Nd:YAG producing 1064 nm. The appropriate laser ...
... is the unique combination laser system for ... of a button switch between SLT or ... Selecta Duet affords you the opportunity to ... the same setting with the benefits inherent ...
Extremely thin and smooth jaws, jaws open to 5.5 mm, cross action....
Medicine Products: